Cyclin-dependent kinase 1 (CDK1) plays a crucial role in establishing metaphase and has also been shown to prevent DNA re-replication. Cyclins B1 and B2 are two known activators of CDK1 operating during mitosis in human cells. Little is known about the specific roles of each of these cyclins in CDK1 activation, but cyclin B2 is thought to play a minor role and to be unable to replace cyclin B1 for mitosis completion. In our study, we found that severe reduction by separate RNA interference of either cyclin B1 or cyclin B2 protein levels results in little or no alteration of the cell cycle and, more specifically, of mitosis progression. In contrast, simultaneous depletion of both B-type cyclins leads to massive accumulation of 4N cells, mitotic failure, premature mitosis exit and DNA rereplication. These defects can be corrected by the ectopic expression of a cyclin B2 resistant to the short hairpin RNA. Altogether, these data show that, in cycling human cells, cyclin B2 can compensate for the downregulation of cyclin B1 during mitosis. They also clearly implicate cyclins B1 and B2 as crucial activators of CDK1 in its biological function of DNA re-replication prevention.
Introduction
Cyclin-dependent kinase 1 (CDK1) is a pivotal mitotic kinase (Lew and Kornbluth, 1996; Morgan, 1997; Ohi and Gould, 1999) present in excess throughout the cell cycle of proliferating cells. Nevertheless, its activity is tightly regulated and depends primarily on the binding of a cyclin-activating subunit. In mammalian cells, two A-type (A1 and A2) and two B-type (B1 and B2) cyclins are able to bind and activate CDK1. Cyclin A2/CDK complexes are necessary and sufficient to drive G 2 cells into prophase (Furuno et al., 1999) and are required for timely nuclear envelope breakdown (NEB) (Gong et al., 2007) . However, the principal activator of CDK1 as a mitosis-promoting factor is cyclin B. The cyclin B/CDK1 activity is necessary to phosphorylate key proteins (for example, lamins, histones, condensins and microtubuleassociated proteins), leading to the radical reorganization of subcellular structures allowing metaphase to take place (Dessev et al., 1991; Peter et al., 1991; Blangy et al., 1995; Morgan, 1995; Kimura et al., 1998) . Nevertheless, CDK1 appears to be dispensable for early mitotic events. Indeed, other kinases, especially those from the Aurora and Polo families are responsible for the initiation of chromosome condensation, nucleoli disassembly and rearrangements of the cytoskeleton leading to rounding up of the cells. In addition, although it was widely accepted that cyclin B/CDK1 is absolutely essential for NEB at the end of prophase, it has recently been shown that this process is only slightly delayed in small interfering RNA-mediated cyclin B knockdown cells (Gong et al., 2007) .
Once metaphase is established, the sequential destruction of cyclins A and B, mediated by the anaphasepromoting complex/cyclosome (APC/C), triggers an irreversible inactivation of the CDK1 activity, which is necessary for mitosis exit. It has recently been shown that chemical inhibition of CDK1 after metaphase arrest promotes a rapid mitosis exit and premature abnormal cytokinesis (Seong et al., 2003; Niiya et al., 2005; Vassilev et al., 2006) .
The two B-type cyclins are localized differently within the cell. Cyclin B1 is essentially cytoplasmic, partially colocalizes with microtubules during interphase, and abruptly translocates into the nucleus upon mitosis entry (Jackman et al., 1995; Hagting et al., 1999) , a process that is delayed in cyclin A2-depleted cells (Gong et al., 2007) . Human cyclin B2 colocalizes with the Golgi apparatus and contributes to its fragmentation during mitosis (Jackman et al., 1995; Draviam et al., 2001) . This difference of localization is in favor of specific roles for each cyclin B as CDK1-activating subunits. This idea has been strengthened by the fact that mutant mice exhibit different phenotypes. Cyclin B1 is essential for viability because nullizygous mice die in utero, whereas cyclin B2 nullizygous mice are viable (Brandeis et al., 1998) . Moreover, microinjection experiments have shown that cyclin B1 alone, but not cyclin B2, can drive G 0 /G 1 cells into mitosis (Draviam et al., 2001) . These data argue for a nonessential role of cyclin B2 in mitosis progression and indicate that, at least under certain conditions, cyclin B1, but not cyclin B2, is sufficient to activate CDK1 in all its cytoplasmic and nuclear functions. This has led to the idea that cyclin B2 could not compensate for a lack of cyclin B1. However, while cyclin B1 depletion by RNA interference in cultured cells has been shown to inhibit proliferation by arresting cells in G 2 /M, (Yuan et al., 2004 (Yuan et al., , 2006 , the degree of cell growth inhibition is dependent on the cell type and, surprisingly, human primary cells do not exhibit any defect, despite a quasi-complete inhibition of cyclin B1/CDK1 kinase activity (Yuan et al., 2004) .
Besides its role in mitosis, CDK1 has been shown to participate in the negative control of DNA re-replication in many systems (Blow and Dutta, 2005) . DNA replication should occur only once per cell cycle. Inhibition of DNA re-replication involves disassembly of the pre-replication complex (pre-RC), thereby negatively regulating re-firing of already used or useless origins at the end of the S phase (Blow and Dutta, 2005) . Redundant mechanisms of regulation include CDK2 and CDK1 inactivating phosphorylations of Cdt1 (Liu et al., 2004; Sugimoto et al., 2004) , origin recognition complexes , cdc6 (Petersen et al., 1999) and replication protein A (RPA), and inhibition of Cdt1 by geminin (Wohlschlegel et al., 2000) . But, although geminin is thought to be the main negative regulator in higher eukaryotes, CDK1 also plays a central role because conditional inactivation of CDK1 in yeast and human cells induces re-replication (Itzhaki et al., 1997) .
Here, we show that, although separate RNA interference-mediated inhibition of cyclin B1 or cyclin B2 expression in human cells has little detectable effect on cell-cycle progression, simultaneous inhibition of both cyclins B1 and B2 leads to a massive accumulation of 4N cells, abnormal mitoses, precocious mitosis exit and re-replication. All these phenotypes can be rescued by re-expression of an ectopic cyclin B2 mutated in the short hairpin (shRNA) recognition site. Altogether, these data show for the first time that in cycling mammalian cultured cells, severe reduction of cyclin B1 does not significantly affect mitosis, because of a compensatory effect of cyclin B2. They also clearly implicate cyclins B1 and B2 in the negative control of rereplication in mammalian cells.
Results
Specific downregulation of cyclin B1 and/or cyclin B2 by RNA interference We designed two shRNAs against the human cyclins B1 and B2 mRNAs. The corresponding sequences were cloned into the pSuper vector and plasmid DNAs were transfected by electroporation, either separately with the empty pSuper vector, or together in the HCT-116 p53À/À cell line (human colorectal cancer cells), a cell line in which the control of pre-RC formation is well documented (Zhu et al., 2004) . Depletion of both B-type cyclins was assessed by real-time reverse transcription-PCR (RT-PCR) analysis, 42 h after transfection ( Figure 1a ). After normalization using the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) sequence as an internal control, we obtained a specific and equivalent extinction of both cyclins B1 and B2 mRNAs (up to 80% of the signal displayed with the empty pSuper vector-transfected cells), whether the two pSuper vectors were transfected separately (pSup B1 or pSup B2), or together (pSup B1 þ B2). Immunoprecipitations followed by in vitro kinase assays in cells depleted of cyclins B1 and B2 showed a 90% reduction of enzymatic activity for cyclin B1/CDK1 after B1 but not B2 depletion, and no significant change in cyclin A2-dependent kinase activity (Supplementary Figure S3a) . Accordingly, the percentage of cyclin B1-positive cells was decreased from 60-65 to 10-12% after cyclin B1 depletion (Supplementary Figure S3b) . Figure 1b shows that cyclins B1 and B2 protein levels were nearly undetectable by western blot, whereas the expression of CDK1 was not altered. Altogether, these results show that a near-complete, specific and equivalent efficiency of inhibition is achieved with the shRNAs targeting cyclins B1 and B2, leading to undetectable or barely detectable protein levels. Similar results were obtained independent of the p53 status, in HCT-116 p53 þ / þ cells (Supplementary Figure S1 ) and HeLa cells (data not shown).
Cyclin B2 becomes essential to prevent 4N arrest and polyploidization when cyclin B1 is downregulated Flow cytometry analysis of HCT-116 p53À/À cells expressing the cyclin B1 shRNA shows only subtle differences in the cell-cycle profile, compared to cells transfected with the empty pSuper vector (Figure 1c) . Indeed, we detected less than a 10% increase in the percentage of G 2 /M cells 42 h after transfection of pSuper cyclin B1, compared to the empty pSuper vector, despite the near-complete extinction of cyclin B1. This result, very surprising regarding the literature because most of the CDK1 activity in G 2 /M is thought to be mediated by the cyclin B1/CDK1 complex, was nevertheless highly reproducible (more than 15 independent experiments performed in HCT-116 p53À/À, HCT-116 p53 þ / þ and HeLa cells). In good agreement with the literature, depletion of cyclin B2 has no effect on the cell-cycle profile (Figure 1c ). In contrast, simultaneous depletion of both cyclins B1 and B2 leads to a significant accumulation of 4N and 8N cells and loss of 2N cells (Figure 1c , right panel), suggesting an unexpected capacity of cyclin B2 to compensate for the downregulation of cyclin B1 in proliferating cells.
Cells depleted of both cyclins B1 and B2 re-replicate their DNA In cells depleted simultaneously of both B-type cyclins, we visualized the appearance of a population with an increased ploidy, characterized by the presence of cells Figure S1 ). To determine whether these 8N cells resulted from the fusion between two 4N cells or DNA re-replication of 4N cells, we performed bromodeoxyuridine (BrdU) labeling to detect cells undergoing replication. Transfected cells were pulse-labeled with BrdU, 42 h after transfection, and immediately analysed by flow cytometry. As shown in Figure 2 , cells with a DNA index between 4N and 8N were positive for BrdU labeling and thus re-replicate DNA after a first complete round of replication. This observation suggests that re-replication is the major mechanism to explain the presence of proliferating 4N cells in the cyclin B1/cyclin B2-depleted population.
Ectopic expression of cyclin B2 restores a quasi-normal cell cycle in cells depleted of cyclins B1 and B2 To confirm the ability of cyclin B2 to compensate for the downregulation of cyclin B1, cells depleted for cyclins B1 and B2 were co-transfected with a pCDNA cyclin B2 expression vector mutated in the shRNA recognition site. As shown in Figure 3a , pCDNA cyclin B2-transfected cells exhibit approximately a two to four-fold increase of cyclin B2, compared to cells transfected with an empty pCDNA (compare lanes 1 and 2 with 5 and 6). When the cyclin B2 shRNA is co-expressed in these cells, the level of cyclin B2 becomes comparable to the endogenous level (compare lanes 1 and 2 with 7 and 8), reflecting inhibition of endogenous but not exogenous Mitosis is impaired in cells depleted of both cyclins B1 and B2 but not in cells depleted of cyclin B1 alone To more precisely characterize the phenotypes associated with depletion of the two B-type cyclins, we performed videomicroscopy with HCT-116 p53À/À transfected cells between 24 and 48 h after transfection (Figure 4a and b) . In this experiment, we monitored the rounding up of the cells typical of mitosis entry, followed by division and flattening out of the two daughter cells. During this period, about 60% of cyclin B2-depleted cells entered and completed mitosis normally within o 60 min (values similar to those obtained after transfection with the empty pSuper vector).
The very weak effect of cyclin B1 depletion on the cell cycle was confirmed, because 50% of cyclin B1-depleted cells timely entered and completed mitosis without any problem detectable by video microscopy. Arrows indicate two normal mitoses in each experiment (Figure 4a ). However, an additional 7% of cells lacking cyclin B1, exhibited strong mitotic defects. They rounded up normally, indicating that they had entered mitosis, but appeared to be arrested in this state for at least 2 h before flattening out without division (not shown). These observations suggest that a minimal threshold level of cyclin B1 is sufficient to complete a normal mitosis, but that under this threshold value, mitosis is impaired. Furthermore, this phenotype was exacerbated in cells depleted in both cyclins B1 and B2. Only 25% of these cells rounded up during the 24 h of observation. Among these cells, 60% (which represents 15% of the total population) eventually flattened out on the plate without division after a delay of about 2 h (arrows indicate two of these abnormal mitoses), whereas only 40% (10% of the total population) exited mitosis timely compared to pSuper-transfected cells, giving birth to two apparently normal daughter cells. The latter cells presumably correspond to the minor fraction of untransfected cells. The average length of abortive mitoses was approximately two to three-fold longer than the average length of normal mitoses in both pSup B1-and pSup B1 þ B2-transfected cells. Abortive mitoses were detected neither in the pSup Ctrl population nor in the pSup B2 population (Figure 4b ). Altogether, these data indicate that cyclin B2 becomes critical for mitosis completion when cyclin B1 is severely downregulated, demonstrating an unexpected capacity of cyclin B2 to compensate for cyclin B1 downregulation.
Cells depleted of cyclins B1 and B2 perform chromosome condensation but exit mitosis prematurely In the cyclins B1 and B2 codepleted cell culture, we attempted to better characterize cells arrested with a round morphology, which is frequently interpreted as a metaphase arrest. To visualize chromatin condensation and establishment of a metaphasic plate after depletion of both cyclins, cells were recorded after co-transfection with a GFP-histone H2B expression vector. As shown in Figure 5a upper panel, whereas control cells exhibit a normal metaphase plate characterized by chromosome alignment in the center of the cell, cyclin B1-and B2-depleted cells exhibit DNA condensation typical of late prophase, but never align their chromosomes even after a 2-h period of arrest in this state. This long arrest is then immediately followed by mitosis exit without division (as shown in Figure 4a ) or, alternatively, abnormal cytokinesis characterized by a complete furrow ingression and the appearance of linked daughter cells (Figure 5a, lower panel) . However, DNA, even if it begins to segregate between these daughter cells, seems to be trapped in the midzone. This phenomenon is readily comparable to the phenotype described after CDK1 chemical inhibition by BMI-1026 or RO-3306 (Seong et al., 2003; Niiya et al., 2005; Vassilev et al., 2006) . However, in our case, the chromosomes eventually collapse, giving rise to a single tetraploid nucleus. We therefore conclude that cells depleted of both cyclins B1 and B2 transiently arrest in late prophase/early prometaphase with condensed chromosomes, but eventually exit this state to directly enter interphase with an increased ploidy. Depending on the cell analysed, mitosis exit can occur with (as shown in Figure 4a ) or without abnormal cytokinesis.
Cells depleted of cyclins B1 and B2 do not accumulate in prometaphase in the presence of nocodazole We reasoned that if cells depleted of the two cyclins B1 and B2 exited mitosis before they reached metaphase, they would not respond to activation of the spindle checkpoint. To address this issue, cells were cultured in the presence of the microtubule depolymerizing agent, nocodazole, from 24 to 42 h after transfection, to activate the spindle checkpoint and specifically arrest them in prometaphase. Time-lapse microscopy revealed that only cells depleted of both cyclins B1 and B2 do not accumulate in mitosis (Supplementary Figure S2a) . To confirm this observation, all cells present on the plate were harvested and analysed by flow cytometry for their DNA content and for the presence of the mitosisspecific MPM2 epitope (Figure 5b ). We counted 50% of prometaphase-arrested MPM-2-positive cells after transfection with the empty pSuper vector, and a similar value (40%) for cells expressing the shRNA against cyclin B2. The percentage of mitotic cells was decreased to 25% in the population expressing the shRNA against cyclin B1, in agreement with our observation that these cells entered mitosis less frequently. Only 9% of mitotic MPM2-positive cells were detected in the population expressing both cyclin B1 and B2 shRNAs, presumably representing weakly or untransfected cells.
The lack of prometaphasic cells in the nocodazoletreated culture depleted of both B-type cyclins was further confirmed by western blot, where an antibody against the Ser-10 phosphorylated histone H3 (which labels cells from prophase to metaphase, Hendzel et al., 1997) revealed a weak signal in cyclin B1-and B2-depleted cells, compared to the control cells or cells depleted of a single cyclin B (Figure 5c ). This implies that the majority of the cells depleted of both cyclins B1 and B2 do not accumulate in prometaphase in the presence of nocodazole. Therefore, the vast majority of 4N cells observed after cyclin B1 and B2 depletion are interphasic.
Taken together, these experiments show that cells lacking cyclins B1 and B2 can enter early mitosis until a round step, which, in this case, does not correspond to a bona fide prometaphasic state, but rather to a late prophase state. They then prematurely exit this early mitosis stage, giving rise to interphasic cells with increased ploidy.
Discussion
We have shown that shRNA-mediated downregulation of both cyclins B1 and B2 in human HCT-116 cells leads to a drastic phenotype of mitotic failure. Few mitoses are detected and most of them are defective. Cells round up and condensate their chromosomes, but exit mitosis prematurely without establishing a metaphase. They then flatten out without division, giving birth to pseudo-G 1 4N cells. In addition, these cells re-replicate their genome, independent of p53. These phenotypes can be almost completely rescued by the ectopic expression of an shRNA-resistant cyclin B2, demonstrating that these cells depend on cyclin B2 for a successful mitosis and prevention of DNA re-replication. In addition, we have observed that shRNA-mediated downregulation of cyclin B1 alone, albeit to barely detectable levels, does not significantly disturb mitosis initiation and completion, except in a minority of cells (o10%), which exit mitosis prematurely as described above for cells knocked down for both cyclins B1 and B2. This result suggests that cyclin B1 expression must be very severely reduced to levels below a threshold to impair efficiently mitosis progression. Only a minority of cells are probably under that threshold and thus exhibit a mitotic Cyclin B2 compensates for cyclin B1 knockdown S Bellanger et al phenotype, whereas the vast majority of cells, although they express cyclin B1 to nearly undetectable levels, accomplish timely mitosis. However, the latter cells now critically depend on cyclin B2 to perform mitosis, although cyclin B2 by itself is nonessential. Altogether, these results demonstrate an unforeseen capacity of cyclin B2 to compensate for a cyclin B1 defect, and point to a critical role of cyclins B1 and B2 as CDK1 activators in the negative control of re-replication in mammalian cells. The critical role of cyclin B2 in supporting mitosis in cyclin B1-depleted cells implies that cyclin B1/CDK1 and cyclin B2/CDK1 share a set of common substrates. When targeted to the cytoplasm by replacing its N-terminal part by the N-terminus of cyclin B1, cyclin B2 acquires the broader properties of cyclin B1 for completing microtubule reorganization (Draviam et al., 2001) , meaning that cyclin B2/CDK1 can recognize and phosphorylate the cyclin B1/CDK1 cytoplasmic substrates. Regarding nuclear substrates, it is not clear whether mammalian cyclin B2 can translocate into the nucleus after G 2 as does its avian ortholog (Gallant and Nigg, 1992) , although it contains a cytoplasmic retention signal (CRS), which has been shown to be both necessary and sufficient to keep it in the cytoplasm during interphase (Pines and Hunter, 1994) . In any case, as cyclin A2 has recently been shown to promote NEB in cells depleted of cyclin B1 (Gong et al., 2007) , cyclin B2/CDK1 would thus have access to all nuclear and cytoplasmic substrates of cyclin B1/CDK1 after NEB, even if it were unable to translocate into the nucleus.
Inhibition of CDK1 activity by the chemical inhibitor BMI-1026 in asynchronous cells leads to either a mitotic arrest, characterized by accumulation of rounded cells, or to precocious cleavage furrow ingression and abnormal cytokinesis, depending on the drug concentration used. Under nocodazole treatment, BMI-1026 leads to mitosis exit and cell spreading without division. Depending on the nocodazole concentration, cells can show membrane blebbing, which is assumed to represent a cortical activity of actomyosin contraction subsequent to formation of ectopic cleavage furrows (Seong et al., 2003; Niiya et al., 2005) . Our observation of precocious mitosis exit and abnormal cytokinesis in proliferating cells downregulated for cyclins B1 and B2 fully reproduces these phenotypes. In addition, in our experiments, no prior arrest in metaphase was needed to observe the phenotype. This indicates that in the absence of both B-type cyclins, metaphase is clearly not a prerequisite to cytokinesis and furrowing. Furthermore, cyclin B is probably necessary to inhibit mitosis exit in the absence of a preliminary metaphase. Importantly, we observed that, after depletion of a single or the two cyclins B, cells in early mitosis always exhibited Mad2-positive kinetochores (Supplementary Figure S2b) , a hallmark of spindle checkpoint activation. This suggested that in the absence of both cyclins B, cells exit mitosis independent of Mad2 signaling pathway.
We also observed that cells depleted of both B-type cyclins are resistant to nocodazole, that is, they exit mitosis and re-replicate their DNA in the presence of the drug. Because these cells do not reach metaphase, they mostly depend on cyclin A2 destruction, a process that is nocodazole-insensitive, to exit mitosis. We thus anticipated that APC/C-mediated proteolysis occurs during premature mitosis exit. Indeed, flow cytometry experiments show that in the population depleted of both B-type cyclins, cells complete two full rounds of DNA replication without chromosome segregation, and sequentially accumulate and degrade cyclin A2. 4N cells that do not express cyclin B1 are able to degrade cyclin A2 at the end of the first round of replication. Cyclin A2 is then re-synthesized during the second round of replication and re-degraded at the end of this second round (Supplementary Figure S1b) . Moreover, we observed by western blot that cyclin A2 is not stabilized in cells depleted of cyclins B1 and B2 (Supplementary Figure S1c) . Altogether, these data suggest that APC/Cmediated proteolysis of cyclin A occurs normally after NEB in these cells depleted of cyclin B. In contrast, the lack of activation of APC/C would have led to stabilization, and therefore accumulation of its substrates. This was clearly not the case because we did not observe any accumulation of either of the following proteins, Cdc20, Cdc6 and geminin (known APC/C Cdh1 substrates degraded in late mitosis and early G 1 ; data not shown). Therefore, the vast majority of 4N cells observed after cyclin B1 and B2 depletion show the characteristics of interphasic G 1 cells that would be able to re-replicate after cyclin A degradation.
Although the major negative control of re-replication in yeast is attributed to the CDK1 homolog cdc2, a similar role of CDK1 in mammals is not so clear. Several years ago, it was proposed that CDK1 took part in the negative control of premature S-phase entry in mammals, because CDK1 lacking human HT2-19 cells became polyploid (Itzhaki et al., 1997) . However, more recently, despite the number of CDK1 inhibitors tested in the literature, only RO-3306-mediated CDK1 inhibition was shown to lead to re-replication in HeLa cells (Vassilev et al., 2006) . Geminin is another possible key component that negatively regulates re-replication in mammalian cells by inhibiting the replication factor Cdt1. Indeed, re-replication observed after geminin depletion in HCT-116 cells is well documented, but appears different from the one we describe here. Geminin-depleted cells do not show the 8N peak we observed after B-type cyclin depletion, but show a more diffuse re-replication distributed over a broad region with a DNA content between 4N and 8N (Zhu et al., 2004) . This result indicates that the re-replication observed after geminin depletion is a partial overreplication and not a full genome duplication. In contrast, in the case of B-type cyclin depletion, the genome seems to be entirely re-replicated, which could be the result of one organized round of re-replication after the mitosis transient arrest. This hypothesis is consistent with our preliminary observation that geminin and Cdc6, two proteins involved in the assembly of pre-RCs, are not deregulated in cyclin B-depleted cells.
In conclusion, when the two B-type cyclins are compromised, cells exhibit a re-replication phenotype similar to the one observed in CDK1-null HT2-19 cells (Itzhaki et al., 1997) . This fits well with a crucial role of cyclin B/CDK1 complexes in this phenotype, probably together with cyclin A/CDK1 complexes. Indeed, re-replication has been reported after cyclin A ablation in drosophila, and also after cyclin A knock down together with Emi-1 in mammals (Mihaylov et al., 2002; Machida and Dutta, 2007) . As cyclin A and B/ CDK1 complexes are activated in a temporal succession, the data provided here, together with these two articles, lead to the idea that cyclin A would participate in early re-replication inhibition in mammals controlled by CDK1, whereas cyclin B complexes would inhibit re-replication later. In our experiments, in which cells are depleted of both B-type cyclins, inhibition of re-replication would depend only on cyclin A/CDK activity. Mitotic degradation of cyclin A by APC/C in the context of cyclin B depletion, would thus license re-replication.
In a more medical point of view, CDK inhibition has been proposed to be used for proliferation inhibition (Lee and Sicinski, 2006) . In the light of our work and recently published data, it is most probable that pharmacological inhibition of CDK1 would not be sufficient to arrest cell proliferation at mitosis and could have adverse effects such as cell polyploidization.
Materials and methods
Cell culture, synchronization, electroporation and video microscopy experiments HCT-116 cells were grown in 6-or 10-cm Petri dishes in McCoy's 5A medium supplemented with 10% fetal calf serum. Transient transfections were done by electroporation. Eighty percent confluent cells were cultured for 4 h before transfection in RPMI 1640 medium (Gibco, Invitrogen, Carlsbad, CA, USA) containing 0.1 mM dithiothreitol (DTT) but lacking calf serum. Immediately before electroporation, the cells were trypsinized, harvested in phosphate-buffered saline (PBS), and resuspended in RPMI medium. About 6 Â 10 6 cells were pipetted into a 4-mm electroporation cuvette and DNA was added (15 mg of each pSuper vector, 20 mg of pCDNA3-mutated cyclin B2 vector or 10 mg of pCDNA3 histone H2B-GFP vector). The mixture was incubated for 5 min at room temperature. Electroporation was performed with a Gene Pulser II electroporation system (300 V, 500 mF; Bio-Rad Laboratories, Hercules, CA, USA). Cells were washed in 10 ml of McCoy's medium, and plated. The medium was changed the day after electroporation, and cells were harvested 42 h after transfection for western blot, quantitative PCR or flow cytometry experiments. The efficiency of transfection was routinely about 90%. For mitosis synchronization, cells were treated with nocodazole (50 ng/ml) from 24 to 42 h after transfection.
For videomicroscopy, cells were transferred to a thermostated chamber (7% CO 2 at 371C) under the lens of the microscope, 24 h after electroporation, where they were maintained for 24 h. Images were captured every 5 min both in phase contrast and fluorescence, using an Axiovert Zeiss microscope. Images were processed with Metamorph software and converted to Adobe Photoshop.
Flow cytometry analyses
Forty-two hours after electroporation, cells were trypsinized, washed and fixed overnight in 70% ethanol/PBS at À201C, rehydrated in PBS and stained for 1 h at 371C with propidium iodide (10 mg/ml) and RNAse A (10 mg/ml). A total of 20 000 cells were acquired by using an EPICS XL flow cytometer (Beckman Coulter Inc., Fullerton, CA, USA) and XL2 software. Statistical analyses were done with WinMDI software.
For BrdU labeling, cells were pulse-labeled with BrdU (10 mM), ethanol-fixed, and treated with 1 ml HCl 2 N/0.5% Triton X100 for 30 min at room temperature. After centrifugation, the pellet was resuspended in 0.1 M Na 2 B 4 O 7 (pH 8.7); cells were then washed with PBS containing 0.5% Tween 20/ 1% bovine serum albumin (BSA). The pellet was resuspended in pure anti-BrdU antibody coupled with fluorescein isothiocyanate (556028; Becton Dickinson Biosciences, Franklin Lakes, NJ, USA), and incubated for 30 min at room temperature. Cells were then washed twice in PBS/Tween/ BSA and labeled for propidium iodide, as described above, before flow cytometry analysis (EPICS XL from Coulter).
For the MPM-2 labeling, fixed cells were washed in PBS, resuspended in anti-MPM2 antibody (ab14581-50, 1/250; Abcam, Cambridge, UK), and incubated for 30 min at room temperature. Cells were then washed twice in PBS, and the pellet was resuspended in the secondary antibody coupled with Alexa 488 (1/1000; A-11001; Molecular Probes, Invitrogen, Carlsbad, CA, USA). After a 1-hour incubation, cells were washed twice with PBS and stained with propidium iodide.
Western blot experiments
Forty-two hours after electroporation, cells were extracted in RIPA buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 0.1% sodium dodecyl sulfate (SDS), 0.5% desoxycholate, 10 mM bglycerophosphate, 1 mM NaF, 0.1 mM NaVO 4 , 1 mM DTT, and protease inhibitors), followed by sonication (41C, 4 Â 30 s, 80%). Equal amounts of total proteins were denatured in Laemmli sample buffer, boiled and separated by 12 or 14% SDS polyacrylamide gel. After electrophoretic transfer, nitrocellulose membranes (Hybond C; Amersham Biosciences, Little Chalfont, UK) were saturated in TNT buffer (25 mM Tris-HCl (pH 7.6), 200 mM NaCl, 0.1% Tween 20) plus 5% milk, incubated with the appropriate first antibodies (anti-cyclin B1 GNS1 (sc-245, 1/200), anti-cyclin B2 (sc-5235, 1/200), anti-CDK1 (sc-54, 1/200), anti-ser10-phosphorylated histone H3 (1/1000; H-0412; Sigma)) overnight, and washed with TNT. Incubation with secondary antibodies coupled with peroxidase (anti-mouse (1/20 000; NA931V; GE Healthcare, Chalfont, St Giles, UK); anti-rabbit (1/20 000; NA934V; GE Healthcare); anti-goat (1/20 000; A9452; Sigma)) was done for 1 h, followed by washing in TNT. Membranes were revealed using the SuperSignal West Pico Chemiluminescent Substrate kit (Pierce Biotechnology, Rockford, IL, USA).
Quantitative real-time reverse transcription-PCR analyses Total RNA (5 mg) was reverse-transcribed into cDNA by MultiScribe reverse transcriptase, using the Reverse Transcription kit superscript II (Invitrogen, Carlsbad, CA, USA), as recommended by the manufacturer. One-fiftieth of the resulting synthesized single-stranded cDNA was used for each PCR reaction in the presence of 3 mM specific primers and Syber green PCR master mix (Applied Biosystems, Foster City, CA, USA). Quantitative PCR was performed on an ABI Prism 7000 (Applied Biosystems), with cycling conditions of 2 0 at 501C, 10 0 at 951C and 40 Â (15 00 at 951C, 1 0 at 601C). After the last cycle, the temperature was progressively raised to provide dissociation curves allowing for the assessment of the purity of the amplified product. Each PCR 96-well plate contained serial dilutions of GAPDH, or 18S ribosomal DNAs as housekeeping genes. Each PCR was performed in duplicate and recorded on a standard curve providing a mean threshold cycle value that was translated into an arbitrary DNA concentration. Cyclin B1 primers used are as follows: 5 0 -AATAAGGAGGGAGCAGTGCG-3 0 and 5 0 -GAAGAGC CAGCCTAGCCTCAG-3 0 . Cyclin B2 primers used are as follows: 5 0 -GCGTTGGCATTATGGATCG-3 0 and 5 0 -TCTT CCGGGAAACTGGCTG-3 0 .
Oligonucleotides used for constructions of shRNAs against cyclins B1 and B2, and for the cyclin B2/shRNA-resistant vector Double-stranded shRNA corresponding to the cDNA sequences of human cyclin B1 (5 0 -GAACAGCUCUUG GGGACAU-3 0 , nucleotides 220-238) and cyclin B2 (5 0 -UGAAACCUACUGCUUCUGU-3 0 , nucleotides 284-302) were designed as recommended (Elbashir et al., 2001) . The cyclin B1 sequence was homologous to a validated Xenopus cyclin B1 siRNA (Zhou et al., 2002) . The cyclin B2 sequence was designed in the same region. No cross-reactive sequence beside the genes of interest was found after a blast analysis against the human genome. DNA oligonucleotides were purchased from QBiogene Research (Morgan Irvine, CA, USA), annealed and subcloned in the pSuper vector as described (Brummelkamp et al., 2002 ). An empty pSuper vector, a pSuper containing a sequence specific for mouse cyclin A2, or a pSuper against HPV-18 E7 protein, both inefficient in cells, served as controls (not shown). The pCDNA3-mutated cyclin B2 vector was constructed by directed mutagenesis. The mutation is as follows: 5 0 -TGAAACCTACTGCTTCTGT-3 0 mutated to 5 0 -TGAAGCCGACGGCATCGGT-3 0 . The mutation conserves the amino-acid sequence of cyclin B2, but the mRNA is not recognized by the shRNA against the cyclin B2 wild-type sequence.
